Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on TERN stock, giving a Buy rating on August 5.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Graig Suvannavejh has given his Buy rating due to a combination of factors surrounding Terns Pharmaceuticals’ prospects. The recent disappointing data from competitors like Viking Therapeutics and Eli Lilly in the oral GLP-1 space highlights potential opportunities for Terns Pharmaceuticals. Specifically, Terns’ candidate, TERN-601, is anticipated to stand out due to its expected differentiation in tolerability, which is a significant concern for current competitors.
Moreover, Terns Pharmaceuticals’ confidence in their product’s superior tolerability profile suggests a competitive edge in the market. The company believes that their approach could address the issues faced by other oral GLP-1 candidates, such as high rates of adverse events and discontinuations. This potential for differentiation and the upcoming key data expected in the fourth quarter of 2025 underpin Suvannavejh’s optimistic outlook and Buy rating for Terns Pharmaceuticals.